Niclosamide is an inhibitor of the Stat3 signaling pathway. Niclosamide inhibits the activation, nuclear translocation and transactivation of Stat3. Niclosamide displays selectivity for Stat3 over Stat1, Stat5, JAK1, JAK2 and Src kinases. Niclosamide inhibits the transcription of Stat3 target genes and induces cell growth inhibition, apoptosis and cell cycle arrest of cancer cells with constitutively active Stat3. Niclosamide is also a FRAP inhibitor via reversible inhibition of mTORC1 signaling and stimulates autophagy in vitro. Niclosamide displays antineoplastic effects in acute myelogenous leukemia (AML) stem cells.
1. Balgi, Aruna D., et al., 2009. Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PloS one. 4(9): e7124. PMID: 19771169
2. Jin, Yanli., et al., 2010. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. Cancer research. 70(6): 2516-27. PMID: 20215516
See how others have used Niclosamide (CAS 50-65-7). Click on the entry to view the PubMed entry .
PMID: # 31451218 Biochem. Biophys. Res. Commun. 518: 638-643.
PMID: # 25465182 Vet Microbiol. 438-447.
PMID: # 30500562 Metab. Clin. Exp. 43-52.
PMID: # 25746684 Vet Microbiol. 370-7.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2021 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.